Recurrent cancer after restorative resection of the rectum As more surgeons have come to use mechanical staplers they are also beginning to question the need for permanent colostomy with total resection of the rectum as the usual treatment for many cancers in this part ofthe bowel.1 2Despite the known high incidence of local recurrence after both abdominoperineal resections and restorative anterior resections of the rectum stapling is becoming more popular. There are considerable discrepancies, as much as tenfold, in the reported incidences of recurrences after resections of rectal cancer, probably owing to the obvious difficulties of detection in the pelvis. The only method of resolving these uncertainties would be the impractical one of routine necropsies. We may be sure, however, that most reports of recurrences underestimate the true incidence.
The importance of the problem was realised many years ago by Miles3 during the development ofabdominoperineal excision of the rectum, and not only does the issue remain as clamant today but it is also likely to become more frequent with the rising tendency to consider restorative resections. Even in centres with the lowest incidences of around 10%4 local recurrences sometimes develop in patients with early (Dukes's grade A) cancers. In the series reported by Goligher et al,4 however, and in many others which included both abdominoperineal and anterior resections local recurrences were most frequent after the removal of Dukes's grade C cancers and those situated in the lower half of the rectum. At least onethird5 and sometimes as many as one-half6 of patients with Dukes's grade B or grade C cancers of the rectum developed local recurrences.
Radiotherapy prescribed either before or after resection has been used with good effect on the local recurrence rates in some trials. Preoperative low-dose regimens appear to yield results which are not improved by higher doses, but this point needs to be critically tested. Systemic chemotherapy, as intravenous 5-fluorouracil for some months after resection, has resulted in apparently increased disease-free intervals in treated patients.7 In a current multicentre randomised trial organised from the National Cancer Institute in the United States of America there are four treatment groups: surgery alone, surgery with additional postoperative radiotherapy, surgery with additional chemotherapy, and surgery with both. All patients had spread of cancer to the regional lymph nodes or penetration of the bowel wall. Postoperative radiotherapy was given for about five weeks, and chemotherapy (5-fluorouracil and CCNU) was continued for 18 months. A preliminary assessment after two and a half years of follow-up showed that only 210% of patients receiving all three treatments had had local or distant recurrences-less than half the incidence of 52% among those treated by rectal excision alone. Just local recurrence was seen in only 300 of those given three treatments and in 19% of those treated by surgery alone.
Topical chemotherapy by the instillation of mercuric perchloride into the isolated distal stump of the rectum has been widely used for many years8 and is thought to limit the incidence of local recurrence.
The current consensus seems to be that a combination of chemotherapy, both systemic and topical, plus irradiation, either preoperative or postoperative, should be used whenever restorative surgery is contemplated, particularly for the highrisk Dukes's grade C cancers and for those occurring in the lower halfofthe rectum. One problem is that rectal cancers cannot be staged accurately before they are excised; all patients should therefore receive multimodal treatment. A pilot study of 12 patients followed up for up to six years after a regimen ofthis type9 showed an anastomotic leak, detected Though improved survival has not been shown after all these regimens, reduced local recurrence itself justifies widespread application of the multimodal approach. Patients should not be rushed to the operating theatre within a few days of diagnosis. The characteristics of the cancer should be thoroughly defined locally and searches made biochemically and radiologically for distant metastases. Consultation between radiotherapist and surgeon should then resolve which multimodal regimen will serve each patient best. Ideally most patients should be entered into controlled trials testing specific questions whose solutions might benefit present and future patients. Unfortunately adequate trial organisations have not developed in Britain; nevertheless, the single randomised trial, organised by the Medical Research Council, has acquired 849 patients in three years for comparison of two regimens of preoperative radiotherapy and non-irradiated controls. The definitive follow-up results are awaited; meanwhile the high incidence and poor outcome of colorectal cancers are clear indications that this is a problematic area which should be given priority.
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The current fashion for jogging, marathon running, and similar forms of sustained exercise must mean that among the population of tiro athletes will be many who are taking regular drug treatment. Undeterred by the ever-increasing documentation of physical disabilities incurred by jogging and irrespective of the lack of any proof from prospective trials of cardiovascular benefit, many patients with mild hypertension and even ischaemic heart disease seem to believe that running will prolong their lives.
Beta-adrenoceptor-blocking drugs have achieved wide acceptance as first-line drug treatment for hypertension and angina. How far this treatment limits exercise capacity is an interesting question,1-4 as is the corollary-the effects on exercise capacity of the various ancillary properties of betablockers, such as cardioselectivity, membrane-stabilising activity, and intrinsic sympathomimetic activity. Most studies have concerned healthy volunteers given a single dose of betablocker and then exercised in the laboratory in constant conditions. Extrapolation from these circumstances to the patient with cardiovascular disease exercising on a cold evening presents problems, so that much of the data must be interpreted with caution.
Beta-adrenoceptor antagonists might affect exercise capacity by several distinct mechanisms. Firstly, they depress total cardiac output through antagonism of cardiac beta1-adrenoceptors. Secondly, they might impair the supply of blood to the muscles by their ability to block beta2-adrenoceptors in the walls of the blood vessels. Thirdly, they affect the metabolism of fatty acids, glucose, lactic acid, and insulin. Fourthly, betablockers may possibly have a direct effect on muscular contraction-a confusing topic on which a recent review by Professor Bowman has shed considerable light.5 The salient facts appear to be as follows.
Adrenoceptors do mediate a direct effect of catecholamines on both fast-contracting and slow-contracting muscles, and these receptors are of the beta2 type. Whereas in general beta1-adrenoceptors (for example, in the heart) are directly innervated by noradrenergic fibres, beta2-adrenoceptors (for example, in the airways and blood vessels) have no direct innervation and respond mainly to adrenaline released from the adrenal medulla. Beta2-adrenoceptors in skeletal muscle appear to fall into a similar category-as is shown, for example, by the common adverse effect of muscular tremor when inhaled beta2 stimulants are used to treat asthma. Strong emotion is also associated with pronounced tremor (though the part played by beta2-adrenoceptors in Parkinsonian tremor is less clear: while beta-blockers are widely used in the management of essential tremor, they are less useful in the treatment of the tremor of Parkinsonism Theoretically, beta1-selective blockers might be expected to have an advantage, but even in single-dose studies in volunteers their expected advantage has been hard to substantiate. Both Pearson and his colleagues from Nottingham,' and Anderson and colleagues from Sydney, Australia,2 showed that 80 mg of propranolol had a similar detrimental effect to 100 mg of metoprolol on both the endurance of exercise and its perceived severity-how tired the volunteers felt.
The effects of 80 mg propranolol and 100 mg atenolol were compared in a further study on volunteers and the results related to muscle fibre composition.3 Individuals with a high percentage of slow-twitch fibres (those concerned with sustained exercise performance and relying on oxidative metabolism to produce energy) ran faster on both occasions than those with a high percentage of fast-twitch fibres (which are concerned with explosive exercise and rely on glycolytic pathways for energy). Propranolol impaired the performance of the persons with a greater proportion of slow-twitch fibres in their leg muscles more than did atenolol-leading the authors to the conclusion that cardioselectivity may be important to joggers who, by virtue of training, may develop a greater preponderance of slow-twitch muscle fibres. This is an interesting conclusion in view of the similarities of adrenoceptor innervation of fasttwitch and slow-twitch fibres.5
Athletes recognise this adverse effect of beta-blockers and some, even those who are medically qualified4-allow themselves the luxury of withdrawing treatment before exercise. Clearly, if exercise is taken regularly such action is incompatible with sustained treatment. Which class of beta-blockers is more contraindicated is by no means clear. At present patients who
